GMP/GPP audits for facilities producing products containing cannabis

Our cannabis facility audits take an in-depth look at your facility, equipment, and processes in order to help ensure compliance with local codes and regulations.

Market overview and forecast

According to research by Graphical Research, North America's cannabidiol (CBD) market size is expected to surpass $61 billion (USD) by 2027. At the global level, the cannabis market of Europe and Asia is estimated to increase at a compound annual growth rate (CAGR) in excess of 30% during this forecast period, as cannabis continues to offer consumers a wide variety of therapeutic benefits.

As a result of its uses, many governments worldwide have legalized or decriminalized cannabis. This will likely lead to the creation of new drugs and other medical advancements. In the U.S., the Food and Drug Administration (FDA) recognizes the potential opportunities that cannabis or cannabis-derived compounds may offer and acknowledges the significant interest in these possibilities.

One concern is that some companies may be marketing products containing cannabis and cannabis-derived compounds in ways that could violate regulatory requirements. This could put the health and safety of consumers of cannabis at risk.

The challenges for cannabis businesses include maintaining compliance with regulatory requirements and continuously finding new solutions to mitigate these risks.

Solutions

UL's offerings include audits for quality, safety and security programs in cultivation and processing facilities.

Our cannabis facility audits take an in-depth look at your facility, equipment, and the associated processes that help ensure compliance with codes and regulations. UL's trusted audits help you strengthen your brand and protect your reputation.

Our current GMP/GPP audits provide quality assurance assessments for cultivators and product manufacturers to verify that current good manufacturing and other processes are followed.

Audits are performed on facilities manufacturing or processing:

- Cannabis–containing products
- Cannabis ingredients
- Cannabis indoor cultivation

Facility audit/certification options for good manufacturing/production practices include:

- Over-the-counter (OTC) drugs – ANSI 455-4, 21 CFR 211
- Cosmetics – ANSI 455-3, ISO 22716
- Dietary supplements – ANSI 455-2
- Cannabis products – Good Production Practices (GPP)

UL conducts audits for and on behalf of:

- Cannabis product manufacturers
- Multistate operators (MSO)
- Brands, brand co-packers, brand licensors
- Governments, regulatory bodies
- Retailers
- Financial institutions, private equity
- Celebrity and brand names/sponsorships associated with cannabis products

Custom audits are available upon request.

Why UL

All auditors are not equal. UL has an unmatched reputation for trust, knowledge and impartiality. We specialize in manufactured products focusing on cosmetics, dietary supplements and OTC drugs.

UL is accredited by the ANSI National Accreditation Board (ANAB) to ISO/IEC 17065 as a Certification Body and ISO/IEC 17020 as an Inspection Body. Our accreditation to these standards establishes a global management system ensuring our programs, processes, and auditors are consistent, impartial and competent to perform the work. UL has a global footprint of auditors offering this solution.

Empowering Trust®